

Press Release

ABL SA group acquires Berlin based Medtech company Humedics

ABL SA acquires the company Humedics GmbH to extend the use of a robust, well-known, and CE-marked technology intended to be used for liver function measurement. Financial terms are not disclosed.

Doctor Chalom Sayada, founder of the ABL SA and managing director of the Humedics declared: “We are proud to take over Humedics, and help promoting and expanding such a technology at the international level.”

A new dedicated strategy is planned for supporting the growth of the Berlin-based company in the future and to establish the LiMAx test as the gold standard for liver function measurement worldwide. In cooperation with well-known scientific institutions, the Humedics technology, which was originally developed for use in liver surgery, is to be expanded to the entire hepatological area, thereby avoiding invasive medical interventions in the future. Finally, remarked Dr. Chalom Sayada: “We are convinced that by acquiring the technology and the know-how of the employees, we will create added value for the benefit of patients.”

Further Information at:

www.ablsa.com

www.humedics.eu

About ABL SA group

Advanced Biological Laboratories (ABL), S.A., is a diagnostic and medical software company founded in 2000 as a spin-off from CRP-Santé (<https://www.lih.lu/>) Luxembourg. ABL's products offer to infectious disease clinicians, virology and microbiology laboratories.

- Assays and standalone software systems for accredited laboratories (i.e. ISO 15189), mainly for microbiology applications (related to HIV, SARS-CoV-2, Tuberculosis, HCV, HBV, HPV, CMV, HPV, Flu, 16s RNA...) for clinical genotyping through sequencing (DeepChek®), DNA and RNA detection and quantification (UltraGene®), including

powerful downstream analysis software applications fully integrated with knowledge databases and analysis systems for capillary and high-throughput Next Generation Sequencing data.

- Clinical software applications for infectious diseases units
- IT dashboards and clinical database aggregation applications for research and clinical management

ABL took in 2013 the rights to all viral hepatitis B & C related assets from EVIVAR MEDICAL as well as a personalized medicine electronic medical record system (EMR) in infectious disease from GlaxoSmithKline in 2016. In July 2018, acquired CDL Pharma to develop CRO related services and assays manufacturing capacity. In June 2019, ABL created its affiliate in the USA (AdvancedDx Biological Laboratories) covering the entire North American territory.

ABL has a comprehensive suite of healthcare management products, including Nadis®, TherapyEdge®, ViroScore®, SeqHepB, DeepChek®, UltraGene®, VisibleChek®, HepatiC®, BacterioChek, MicrobioChek and the DPM used for data and patient management, monitoring and personalized reporting applications. Since 2012, some of ABL's products are CE-IVD marked. In 2020, ABL got CE-IVD marking for its DeepChek®-HIV assays as well as for its UltraGene Combo2ScreenSARS-CoV-2 assay. In 2021 ABL got CE-IVD marking for UltraGene SARS-CoV-2 Multi Variants Deletions V1 assay as well as UltraGene Assay SARS-CoV-2 Triplex, Screening, Multi-Variants and Typing V1. The other products are currently available for Research Use Only.

About Humedics GmbH

Based in Berlin, Germany, **Humedics GmbH** is specialised in rapid and accurate liver function measurement using the LiMAx® test, an innovative technology for analysing exhaled air. The LiMAx® test provides physicians with a method for quantitatively assessing an individual patient's liver function capacity within minutes. This enables physicians to select treatment strategies and follow disease progression based on up-to-date knowledge of the functional health of the liver. Current applications, which have already been published in prestigious medical journals, include liver function diagnosis before and after liver transplantation, surgical planning for liver surgery (such as assessing how much liver tissue can be removed without increasing the risk of acute liver failure), and assessment of liver diseases such as fibrosis and cirrhosis. At present, more than 20 studies regarding new diagnostic indications are being conducted. These include diagnosing and staging of chronic liver diseases such as non-alcoholic steatohepatitis (NASH), as well as selecting, monitoring and managing different oncology treatment options. These studies, initiated by researchers, have already provided evidence of further potential for the LiMAx® tests. The LiMAx® test is in routine clinical use at more than 30 leading university hospitals in Europe. So far, more than 20,000 LiMAx® tests have been performed. The LiMAx® test is commercially available in Germany, Austria and the UK.